**Name Surname**
Ika Nurlaila

**Doctorate**
Cancer Immunology and Immunotherapy

**Education**
PhD, Cancer Immunology and Immunotherapy, University of Birmingham, United Kingdom 2015-2019
MHSc ,Cancer Immunology, University of Brunei Darussalam, Brunei Darussalam, 2010-2012
BSc, Biology (major: molecular biology), Brawijaya University, Indonesia, 2000-2004

**Experience**
2021 Research Scientist at the National Research and Innovation Agency (BRIN), Tangerang Selatan, Indonesia
2020-2021 Postdoctoral fellow at the Department of Integrative Biotechnology and Bioengineering, Sungkyunkwan University, South Korea
2019-2020 Researcher at the Bioinformatics and Data Science Research Center, Jakarta, Indonesia
2013-2015 Lecturer at the Department of Biotechnology, Faculty of Life Sciences, Surya University, Tangerang, Indonesia
2009-2010 Research Assistant at the Department of Microbiology, Indonesia Institute of Sciences (LIPI), Cibinong, Indonesia
2008-2009 Research Assistant at the US-Naval Medical Research Unit-2 (US-NAMRU-2), Jakarta, Indonesia

**Research Interests**

- Cancer Immunology
- Cell and Molecular Biology
- Biotechnology
- Translational medicine
- Nanobiology particularly for the generification of precision medicine for cancer

**Last 5 Publications**

1. **Nurlaila**, I. Deciphering Antigen Processing Machinery (APM) as One of the Determinants for Responsiveness of Affected Patients towards Anticancer Immunotherapy. 2024. Asian Pacific Journal of Cancer Prevention. Dec 1;25(12):4457-4464. doi: 10.31557/APJCP.2024.25.12.4457. https://pubmed.ncbi.nlm.nih.gov/39733439/

2. **Nurlaila, I.** The Silent Threat of Interplay between Immune Checkpoint Inhibitors and Herbal Medicines. Asian Pacific Journal of Cancer Prevention. 2024. Oct 1;25(10):3337-3338. doi: 10.31557/APJCP.2024.25.10.3337. https://pubmed.ncbi.nlm.nih.gov/39470998/

3. **Nurlaila, I.,** Rajabto, W., Ningsih, F.N., Sulistiyaningsih, E., Ratih, U.S. Impaired Granularity in T cell Subsets but not in B cell Favors the Carcinogenesis of the Breast: a preliminary study in Indonesian women cohort. Asian Pacific Journal of Cancer Prevention 2025. 26(1) (Accepted).

4. **Nurlaila I**, Pambudi S. The evolvement of breast cancer therapies: What we have done and where all these head off. Saudi Med J. 2024 Apr;45(4):331-340. doi: 10.15537/smj.2024.45.4.20230492. PMID: 38657992. Impact Factor 1.48; Area and position: Medicine (miscellaneous)

5. **Nurlaila I**, Nurhasanah A. Human Mammary Tumor Virus (HMTV) Reshapes Risk of Women Developing Breast Cancer: Re-visiting an Under considered Variable in Tumorigenesis of the Breast. Asian Pac J Cancer Prev. 2024 Jan 1;25(1):1-2. doi: 10.31557/APJCP.2024.25.1.1. PMID: 38285762; PMCID: PMC10911737. Impact Factor 1.65; Area and position: Oncology

**Memberships**

2023-present Society for Immunotherapy of Cancer (SITC)
2022-present European Association for Cancer Research (EACR), also serves as a non-European EACR ambassador

**Awards**

2004 Best Youth Researcher for Natural and Life Sciences (LIPI)
2004 Outstanding student of the Faculty of Mathematics and Natural Sciences, Brawijaya University
2010 Grantee of Graduate Research Scholarship from the University of Brunei Darussalam
2019 Awardee of Endowment fund for Higher Education
2022 Best paper award of the International Conference on Biospheric Harmony Advanced Research, Jakarta, June 22-23, 2022
2023 Best Presenter in the ocassion of the 3rd International Conference on Intelligent Cybernetics Technology & Applications 2023 Bali, 13-15 December 2023
2023-2024 Grantee of Research Organization for Health's funding for Cancer immunology research (early career)
2024 Grantee of Research Organization for Electronics and Bioinformatics' funding for whole transcriptomic study in cancer
2024 Fellow of SITC Women in Cancer Immunotherapy Network's (WIN) Leadership Institute
2024 Fellow of Editorial Board of Asian Pacific Journal of Cancer Prevention